The burden of peripheral artery disease and the role of antiplatelet therapy

Postgraduate Medicine

Volumn 121, Issue 4, 2009, Pages 123-135

  Aronow, Herbert ^a,c   Hiatt, William R ^b  

^a ST JOSEPH MERCY HOSPITAL   (United States)

^b UNIVERSITY OF COLORADO   (United States)

^c Michigan Heart and Vascular Institute   (United States)

Author keywords

Ankle brachial index; Atherosclerosis; Cardiovascular risk factors; Peripheral artery disease

Indexed keywords

ACETYLSALICYLIC ACID; ACETYLSALICYLIC ACID PLUS DIPYRIDAMOLE; ANTITHROMBOCYTIC AGENT; C REACTIVE PROTEIN; CILOSTAZOL; CLOPIDOGREL; DIPYRIDAMOLE; FIBRINOGEN; FOLIC ACID; HEMOGLOBIN A1C; HOMOCYSTEINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; TICLOPIDINE; WARFARIN;

ANKLE BRACHIAL INDEX; ARTERY DISEASE; ATHEROSCLEROSIS; BLEEDING; BRAIN BLOOD VESSEL; CARDIOVASCULAR RISK; CIGARETTE SMOKING; CLAUDICATION; CLINICAL TRIAL; CORONARY ARTERY; DIABETES MELLITUS; DIAGNOSTIC ERROR; DIARRHEA; DYSLIPIDEMIA; ECONOMIC ASPECT; FIBRINOGEN BLOOD LEVEL; GASTROINTESTINAL HEMORRHAGE; GLYCEMIC CONTROL; HEART DEATH; HEART INFARCTION; HEMOGLOBIN BLOOD LEVEL; HIGH RISK PATIENT; HOSPITALIZATION; HUMAN; HYPERHOMOCYSTEINEMIA; HYPERTENSION; KIDNEY DISEASE; LIFESTYLE MODIFICATION; MONOTHERAPY; MORTALITY; PRACTICE GUIDELINE; PROTEIN BLOOD LEVEL; QUESTIONNAIRE; RASH; REVASCULARIZATION; REVIEW; RISK FACTOR; SCREENING; SHORT FORM 36; SKIN BRUISING; SMOKING CESSATION; STROKE; THROMBOSIS;

ATHEROSCLEROSIS; COST OF ILLNESS; HUMANS; PERIPHERAL VASCULAR DISEASES; PLATELET AGGREGATION INHIBITORS; PREVALENCE; RISK FACTORS;

EID: 68249094906     PISSN: 00325481     EISSN: 19419260     Source Type: Journal    
DOI: 10.3810/pgm.2009.07.2038     Document Type: Review

References (89)

1. Bhatt DL, Steg PG, Ohman Em, et al. International prevalence, recognition, and treatment of cardiovascular risk factors in outpatients with atherothrombosis. JAMA. 2006;295(2):180-189. (Pubitemid 43076437)
2. Steg PG, Bhatt DL, Wilson PW, et al. One-year cardiovascular event rates in outpatients with atherothrombosis. JAMA. 2007;297(11):1197-1206. (Pubitemid 46465728)
3. Ostchega Y, Paulose-Ram R, Dillon CF, Gu Q, Hughes JP. Prevalence of peripheral arterial disease and risk factors in persons aged 60 and older: data from the National Health and Nutrition Examination Survey 1999-2004. J Am Geriatr Soc 2007;55(4):583-589.
4. Criqui MH, Fronek A, Barrett-Connor E, Klauber MR, Gabriel S, Goodman D. The prevalence of peripheral arterial disease in a defined population. Circulation. 1985;71(3):510-515. (Pubitemid 15133809)
5. Stoffers HE, Rinkens PE, Kester AD, Kaiser V, Knottnerus JA. The prevalence of asymptomatic and unrecognized peripheral arterial occlusive disease. Int J Epidemiol. 1996;25(2):282-290. (Pubitemid 26137108)
6. Aronow WS, Ahn C, Gutstein H. Prevalence and incidence of cardiovascular disease in 1160 older men and 2464 older women in a long-term health care facility. J Gerontol A Biol Sci Med Sci. 2002;57(1):M45-M46. (Pubitemid 34074445)
7. Ness J, Aronow WS, Ahn C. Risk factors for symptomatic peripheral arterial disease in older persons in an academic hospital-based geriatrics practice. J Am Geriatr Soc. 2000;48(3):312-314. (Pubitemid 30164216)
8. Selvin E, Erlinger TP. Prevalence of and risk factors for peripheral arterial disease in the United States: results from the National Health and Nutrition Examination Survey, 1999-2000. Circulation. 2004;110(6):738-743.
9. Hirsch AT, Haskal ZJ, Hertzer NR, et al. ACC/AHA 2005 Practice Guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): a collaborative report from the American Association for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Peripheral Arterial Disease): endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation; National Heart, Lung, and Blood Institute; Society for Vascular Nursing; TransAtlantic Inter-Society Consensus; and Vascular Disease Foundation. Circulation. 2006;113(11):e463-e654.
10. Scottish Intercollegiate Guidelines Network. Diagnosis and management of peripheral arterial disease: a national clinical guideline. Edinburgh, Scotland: SIGN; 2006
11. Dumville JC, Lee AJ, Smith FB, Fowkes FG. The health-related quality of life of people with peripheral arterial disease in the community: the Edinburgh Artery Study. Br J Gen Pract. 2004;54(508):826-831.
12. Collins TC, Suarez-Almazor M, Bush RL, Petersen NJ. Gender and peripheral arterial disease. J Am Board Fam Med. 2006;19(2):132-140.
13. Ness J, Aronow WS. Prevalence of coexistence of coronary artery disease, ischemic stroke, and peripheral arterial disease in older persons, mean age 80 years, in an academic hospital-based geriatrics practice. J Am Geriatr Soc. 1999;47(10):1255-1256. (Pubitemid 29473300)
14. Fowkes FG, Low LP, Tuta S, Kozak J; AGATHA Investigators. Ankle-brachial index and extent of atherothrombosis in 8891 patients with or at risk of vascular disease: results of the international AGATHA study. Eur Heart J. 2006;27(15):1861-1867. (Pubitemid 44297394)
15. American Cancer Society. Cancer facts and figures 2007. Atlanta, GA: American Cancer Society; 2007.
16. Leng GC, Lee AJ, Fowkes FG, et al. Incidence, natural history and cardiovascular events in symptomatic and asymptomatic peripheral arterial disease in the general population. Int J Epidemiol. 1996;25(6):1172-1181. (Pubitemid 27013522)
17. Criqui MH, Langer RD, Fronek A, et al. Mortality over a period of 10 years in patients with peripheral arterial disease. N Engl J Med. 1992;326(6):381-386.
18. Jaff MR. Peripheral arterial disease costlier to treat than coronary artery disease. International Symposmm on Endovascular Therapy, Hollywood, FL; 2008.
19. Hirsch AT, Hartman L, Town RJ, Virnig BA. National health care costs of peripheral arterial disease in the Medicare population. Vasc Med. 2008;13(3):209-215.
20. The SAGE Group. Peripheral Arterial Disease (PAD)-related amputations cost an estimated $10 billion. http://thesagegroup.us/press%20releases/ amputation%20sept04.html. Accessed July 1, 2006.
21. Hirsch AT, Murphy TP, Lovell MB, et al. Gaps in public knowledge of peripheral arterial disease: the first national PAD public awareness survey. Circulation. 2007;116(18):2086-2094.
22. Hirsch AT, Criqui MH, Treat-Jacobson D, et al. Peripheral arterial disease detection, awareness, and treatment in primary care. JAMA. 2001;286(11):1317-1324. (Pubitemid 33015522)
23. Dormandy JA, Rutherford RB. Management of peripheral arterial disease (PAD). TASC Working Group. TransAtlantic Inter-Society Consensus (TASC). J Vasc Surg. 2000;31(1 pt 2):S1-S296.
24. Leng GC, Fowkes FG. The Edinburgh Claudication Questionnaire: an improved version of the WHO/Rose Questionnaire for use in epidemiological surveys. J Clin Epidemiol. 1992;45(10):1101-1109.
25. Regensteiner JG, Steiner JF, Panzer RJ, Hiatt WR. Evaulation of walking impairment by questionnaire in patients with peripheral arterial disease. J Vasc Med Biol. 1990;2:142-152.
26. Spertus J, Jones P, Poler S, Rocha-Singh K. The peripheral artery questionnaire: a new disease-specific health status measure for patients with peripheral arterial disease. Am Heart J. 2004;147(2):301-308. (Pubitemid 38180531)
27. Norgren L, Hiatt WR, Dormandy JA, et al. Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II). Eur J Vasc Endovasc Surg. 2007;33(suppl 1):S1-S75. (Pubitemid 46068992)
28. Sikkink CJ, van Asten WN, van't Hof MA, van Langen H, van der Vliet JA. Decreased ankle/brachial indices in relation to morbidity and mortality in patients with peripheral arterial disease. Vasc Med. 1997;2(3):166-173.
29. Newman AB, Siscovick DS, Manolio TA, et al. Ankle-arm index as a marker of atherosclerosis in the Cardiovascular Health Study. Cardiovascular Heart Study (CHS) Collaborative Research Group. Circulation. 1993;88(3):837-845.
30. Fowkes FG, Murray GD, Butcher I, et al. Ankle brachial index combined with Framingham Risk Score to predict cardiovascular events and mortality: a meta-analysis. JAMA. 2008;300(2):197-208. (Pubitemid 351969304)
31. He Y, Jiang Y, Wang J, Fan L, Li X, Hu FH. Prevalence of peripheral arterial disease and its association with smoking in a population-based study in Beijing, China. J Vasc Surg. 2006;44(2):333-338. (Pubitemid 44142914)
32. Aboyans V, Criqui MH, Denenberg JO, Knoke JD, Ridker PM, Fronek A. Risk factors for progression of peripheral arterial disease in large and small vessels. Circulation. 2006;113(22):2623-2629. (Pubitemid 43948011)
33. Welligendael EM, Teijink JA, Bartelink ML, Peters RJ, Buller HR, Prins MH. Smoking and the patency of lower extremity bypass grafts: a meta-analysis. J Vasc Surg. 2005;42(1):67-74.
34. Tapp RJ, Balkau B, Shaw JE, Valensi P, Cailleau M, Eschwege E. Association of glucose metabolism, smoking and cardiovascular risk factors with incident peripheral arterial disease: the DESIR study. Atherosclerosis. 2007;190(1):84-89. (Pubitemid 44920232)
35. Leibson CL, Ransom JE, Olson W, Zimmerman BR, O'Fallon WM, Palumbo PJ. Peripheral arterial disease, diabetes, and mortality. Diabetes Care. 2004;27(12):2843-2849. (Pubitemid 39565047)
36. Kallio M, Forsblom C, Groop PH, Groop L, Lepantalo M. Development of new peripheral arterial occlusive disease in patients with type 2 diabetes during a mean follow-up of 11 years. Diabetes Care. 2003;26(4):1241-1245. (Pubitemid 36929279)
37. Wattanakit K, Folsom AR, Selvin E, et al. Risk factors for peripheral arterial disease incidence in persons with diabetes: the Atherosclerosis Risk in Communities (ARIC) Study. Atherosclerosis. 2005;180(2):389-397. (Pubitemid 41072911)
38. Khattab AD, Ali IS, Rawlings B. Peripheral arterial disease in diabetic patients selected from a primary care setting: implications for nursing practice. J Vasc Nurs. 2005;23(4):139-148. (Pubitemid 41751021)
39. Carmona GA, Hoffmeyer P, Herrmann FR, et al. Major lower limb amputations in the elderly observed over ten years: the role of diabetes and peripheral arterial disease. Diabetes Metab. 2005;31(5):449-454. (Pubitemid 41639967)
40. Malmstedt J, Wahlberg E, Jörneskog G, Swedenborg J. Influence of perioperative blood glucose levels on outcome after infrainguinal bypass surgery in patients with diabetes. Br J Surg. 2006;93(11):1360-1367. (Pubitemid 44736086)
41. Wattanakit K, Folsom AR, Selvin E, Coresh J, Hirsch AT, Weatherley BD. Kidney function and risk of peripheral arterial disease: results from the Atherosclerosis Risk in Communities (ARIC) Study. J Am Soc Nephrol. 2007;18(2):629-636. (Pubitemid 46193329)
42. Owens CD, Ho KJ, Kim S, et al. Refinement of survival prediction in patients undergoing lower extremity bypass surgery: stratification by chronic kidney disease classification. J Vasc Surg. 2007;45(5):944-952. (Pubitemid 46634932)
43. O'Hare AM, Bertenthal D, Shlipak MG, Sen S, Chren MM. Impact of renal insufficiency on mortality in advanced lower extremity peripheral arterial disease. J Am Soc Nephrol. 2005;16(2):514-519. (Pubitemid 41725149)
44. Lange S, Trampisch HJ, Haberl R, et al. Excess 1-year cardiovascular risk in elderly primary care patients with a low ankle-brachial index (ABI) and high homocysteine level. Atherosclerosis. 2005;178(2):351-357. (Pubitemid 40193451)
45. Taute BM, Taute R, Heins S, Behrmann C, Podhaisky H. Hyperhomocysteinemia: marker of systemic atherosclerosis in peripheral arterial disease. Int Angiol. 2004;23(1):35-40. (Pubitemid 38811564)
46. Taylor LM Jr, Moneta GL, Sexton GJ, Schuff RA, Porter JM. Prospective blinded study of the relationship between plasma homocysteine and progression of symptomatic peripheral arterial disease. J Vasc Surg. 1999;29(1):8-19.
47. Ridker PM, Cushman M. Stampfer MJ, Tracy RP, Hennekens CH. Plasma concentration of C-reactive protein and risk of developing peripheral vascular disease. Circulation. 1998;97(5):425-428. (Pubitemid 28090212)
48. Allison MA, Criqui MH, McClelland RL, et al. The effect of novel cardiovascular risk factors on the ethnic-specific odds for peripheral arterial disease in the Multi-Ethnic Study of Atherosclerosis (MESA). J Am Coll Cardiol. 2006;48(6):1190-1197.
49. Vu JD, Vu JB, Pio JR, et al. Impact of C-reactive protein on the likelihood of peripheral arterial disease in United States adults with the metabolic syndrome, diabetes mellitus, and preexisting cardiovascular disease. Am J Cardiol. 2005;96(5):655-658.
50. Tzoulaki I, Murray GD, Lee AJ, Rumley A, Lowe GD, Fowkes FG. Inflammatory, haemostatic, and rheological markers for incident peripheral arterial disease: Edinburgh Artery Study. Eur Heart J. 2007;28(3):354-362. (Pubitemid 46254637)
51. Wildman RP, Muntner P, Chen J, Sutton-Tyrrell K, He J. Relation of inflammation to peripheral arterial disease in the national health and nutrition examination survey, 1999-2002. Am J Cardiol. 2005;96(11):1579-1583.
52. Vainas T, Stassen FR, de Graaf R et al. C-reactive protein in peripheral arterial disease: relation to severity of the disease and to future cardiovascular events. J Vasc Surg. 2005;42(2):243-251. (Pubitemid 41139229)
53. McDermott MM, Ferrucci L, Liu K, et al. D-dimer and inflammatory markers as predictors of functional decline in men and women with and without peripheral arterial disease. J Am Geriatr Soc. 2005;53(10):1688-1696. (Pubitemid 43109931)
54. Engström G, Site-Flondell D, Lindblad B, Janzon L, Lindgärde F. Risk of treatment of peripheral arterial disease is related to inflammation-sensitive plasma proteins: a prospective cohort study. J Vasc Surg. 2004;40(6):1101-1105. (Pubitemid 40037277)
55. Doweik L, Maca T, Schillinger M, Budinsky A, Sabeti S, Minar E. Fibrinogen predicts mortality in high risk patients with peripheral artery disease. Eur J Vasc Endovasc Surg. 2003;26(4):381-386. (Pubitemid 37266146)
56. Heart Protection Study Collaborative Group. MRC-/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet. 2002;360(9326):7-22.
57. Radack K, Deck C. Beta-adrenergic blocker therapy does not worsen intermittent claudication in subjects with peripheral arterial disease. A meta-analysis of randomized controlled trials. Arch Intern Med. 1991;151(9):1769-1776.
58. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G; The Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med. 2000;342(3):145-153.
59. Dluhy RG, McMahon GT. Intensive glycemic control in the ACCORD and ADVANCE trials. N Engl J Med. 2008;358(24):2630-2633.
60. Merchant AT, Hu FB, Spiegelman D, Willett WC, Rimm EB, Ascherio A. The use of B vitamin supplements and peripheral arterial disease risk in men are inversely related. J Nutr. 2003;133(6):2863-2867. (Pubitemid 37099772)
61. Carrero JJ, Lopez-Huertas E, Salmeron LM, Baaro L, Ros E. Daily supplementation with (n-3) PUFAs, oleic acid, folic acid, and vitamins B-6 and E increases pain-free walking distance and improves risk factors in men with peripheral vascular disease. J Nutr 2005;135(6):1393-1399. (Pubitemid 40799601)
62. Schernthaner GH, Plank C, Minar E, Bieglmayer C, Koppensteiner R, Schernthaner G. No effect of homocysteine-lowering therapy on vascular inflammation and haemostasis in peripheral arterial occlusive disease. Eur J Clin Invest. 2006;36(5):333-339.
63. CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet. 1996;348(9038):1329-1339.
64. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ. 2002;324(7329):71-86.
65. Berger JS, Krantz MJ, Kittelson JM, Hiatt WR. Aspirin for the prevention of cardiovascular events in patients with peripheral artery disease: a meta-analysis of randomized trials. JAMA. 2009;301(18):1909-1919.
66. Bhatt DL, Flather MD, Hacke W, et al. Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the CHARISMA trial. J Am Coll Cardiol. 2007;49(19):1982-1988. (Pubitemid 46694290)
67. Mukherjee D, Topol EJ, Moliterno DJ, et al. Extracardiac vascular disease and effectiveness of sustained clopidogrel treatment. Heart. 2006;92(1):40-51. (Pubitemid 43021852)
68. Dorffler-Melly J, Koopman MM, Prins MH, Buller HR. Antiplatelet and anticoagulant drugs for prevention of restenosis/reocclusion following peripheral endovascular treatment. Cochrane Database Syst Rev. 2005;(1):CD002071.
69. Park SW, Lee CW, Kim HS, et al. Effects of cilostazol on angiographic restenosis after coronary stent placement. Am J Cardiol. 2000;86(5):499-503.
70. Kwon SU, Cho YJ, Koo JS, et al. Cilostazol prevents the progression of the symptomatic intracranial arterial stenosis: the multicenter double-blind placebo-controlled trial of cilostazol in symptomatic intracranial arterial stenosis. Stroke. 2005;36(4):782-786. (Pubitemid 40490625)
71. Anand SS, Yusuf S. Oral anticoagulants in patients with coronary artery disease. J Am Coll Cardiol. 2003;41(4 suppl):62S-69S. (Pubitemid 36223349)
72. Mohler ER 3ed. Atherothrombosis - wave goodbye to combined anticoagulation and antiplatelet therapy? N Engl J Med. 2007;357(3):293-296.
73. Stewart KJ, Hiatt WR, Regensteiner JG, Hirsch AT. Exercise training for claudication. N Eng J Med. 2002;347(24):1941-1951.
74. de Vries SO, Visser K, de Vries JA, Wong JB, Donaldson MC, Hunink MG. Intermittent claudication: cost-effectiveness of revascularization versus exercise therapy. Radiology. 2002;222(1):25-36.
75. Regensteiner JG, Ware JE Jr, McCarthy WJ, et al. Effect of cilostazol on treadmill walking, community-based walking ability, and health-related quality of life in patients with intermittent claudication due to peripheral arterial disease: meta-analysis of six randomized controlled trials. J Am Geriatr Soc. 2002;50(12):1939-1946.
76. Thompson PD, Zimet R, Forbes WP, Zhang P. Meta-analysis of results from eight randomized, placebo-controlled trials on the effect of cilostazol on patients with intermittent claudication. Am J Cardiol. 2002;90(12):1314-1319. (Pubitemid 35449476)
77. Girolami B, Bernardi E, Prins MH, et al. Treatment of intermittent claudication with physical training, smoking cessation, pentoxifylline, or nafronyl: a meta-analysis. Arch Intern Med. 1999;159(4):337-345. (Pubitemid 29091621)
78. Hood SC, Moher D, Barber GG. Management of intermittent claudication with pentoxifylline: meta-analysis of randomized controlled trials. CMAJ. 1996;155(8):1053-1059. (Pubitemid 26358727)
79. Bianchi C, Montalvo V, Ou HW, Bishop V, Abou-Zamzam AM. Pharmacologic risk factor treatment of peripheral arterial disease is lacking and requires vascular surgeon participation. Ann Vasc Surg. 2007;21(2):163-166. (Pubitemid 46367551)
80. Khan S, Flather M, Mister R, et al. Characteristics and treatments of patients with peripheral arterial disease referred to UK vascular clinics: results of a prospective registry. Eur J Vasc Endovasc Surg. 2007;33(4):442-450. (Pubitemid 46336595)
81. Froehlich JB, Mukherjee D, Avezum A, et al. Association of peripheral artery disease with treatment and outcomes in acute coronary syndromes. The Global Registry of Acute Coronary Events (GRACE). Am Heart J. 2006;151:1123-1128.
82. Conte MS, Bandyk DF, Clowes AW, Moneta GL, Namini H, Seely L. Risk factors, medical therapies and perioperative events in limb salvage surgery: observations from the PREVENT III multicenter trial. J Vasc Surg. 2005;42(3):456-464. (Pubitemid 41323832)
83. Bradley L, Kirker SG. Secondary prevention of arteriosclerosis in lower limb vascular amputees: a missed opportunity. Eur J Vasc Endovasc Surg. 2000;32(5):491-493.
84. Hasimu B, Li J, Yu J, et al. Evalualion of medical treatment for peripheral arterial disease in Chinese high-risk patients. Circ J. 2007;71(1):95-99. (Pubitemid 46045557)
85. Blacher J, Cacoub P, Luizy F, et al. Peripheral arterial disease versus other localizations of vascular disease: the ATTEST study. J Vasc Surg. 2006;44(2):314-318. (Pubitemid 44160761)
86. Smaha LA. The American Heart Association Get With The Guidelines program. Am Heart J. 2004;148(5 suppl):S46-S48. (Pubitemid 39425040)
87. Rehring TF, Stolcpart RS, Sandhoff BG, Merenich JA, Hollis HW. Effect of a clinical pharmacy service on lipid control in patients with peripheral arterial disease. J Vasc Surg. 2006;43(6):1205-1210.
88. Mukherjee D, Munir K, Hirsch AT, et al. Development of a multicenter peripheral arterial interventional database: the PVD-QI2. Am Heart J. 2005;149(6):1003-1008. (Pubitemid 40848144)
89. Criqui MH, Denenberg JO, Bird CE, Fronek A, Klauber MR, Langer RD. The correlation between symptoms and non-invasive test results in patients referred for peripheral arterial disease testing. Vasc Med. 1996;1(1):65-71. (Pubitemid 26153813)